COVID‐19 infection in patients with sickle cell disease

Hussain, Faiz; Njoku, Franklin; Saraf, Santosh L.; Molokie, Robert E.; Gordeuk, Victor R.; Han, Jin

doi:10.1111/bjh.16734

Cited by 95 publications

(130 citation statements)

References 4 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…2 A study by Hussain et al reported four SCD cases that tested positive for COVID-19. 3 These cases initially presented to the emergency department for a typical vaso-occlusive crisis (VOC), and the clinical course of their SARS-CoV-2 infection was rather mild. Patients had a history of respiratory complications, such as acute chest syndrome (ACS), asthma, or pulmonary embolism, which may be potential risk factors for progressive COVID-19 pulmonary disease in patients with SCD.…”

mentioning

confidence: 99%

“…Patients had a history of respiratory complications, such as acute chest syndrome (ACS), asthma, or pulmonary embolism, which may be potential risk factors for progressive COVID-19 pulmonary disease in patients with SCD. 3 A series of isolated cases of ACS in SCD patients positive for COVID-19 has been recently reported. 4,5 Therefore, very little clinical experience of infected patients with SCD currently exists.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations

et al. 2020

View full text Add to dashboard Cite

mentioning

confidence: 99%

mentioning

confidence: 99%

Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations

et al. 2020

View full text Add to dashboard Cite

“…In France, a 45‐years‐old SCD patient suffering from COVID‐19 has been successfully treated with Tocilizumab (TCZ), an anti‐human IL‐6 receptor monoclonal antibody [7]. Moreover, other SCD cases affected by SARS‐CoV‐2 in the United States [8,9] and the Netherlands [10] population have been recently reported.…”

Section: Discussionmentioning

confidence: 99%

Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity

Quaresima

Naldini

et al. 2020

eJHaem

View full text Add to dashboard Cite

“…The management of acute chest syndrome in sickle cell anaemia is similar in that they both require oxygen therapy, antibiotic and exchange blood transfusion [16]. Despite the highly contagious nature of this COVID-19 and the immunosuppression in sickle cell disease, there were few studies done on COVID-19 in patients with sickle cell disease [18,19,20,21]. Most of these studies were case reports and case series that discussed the pattern of presentations and treatment modalities of COVID-19 in patients with sickle cell disease.…”

Section: Introductionmentioning

confidence: 99%

Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 – Review of Literatures

Abiola¹,

Abdul²,

Muhammad³

2020

AJLM

View full text Add to dashboard Cite

Sickle cell disease (SCD) is the co-inheritance of HbS with other abnormal haemoglobin. COVID-19 is a severe acute respiratory distress syndrome caused by coronavirus 2 infections. The immunosuppression and chronic inflammatory states in patients with SCD predispose them to severe form of COVID-19. The few case studies on sickle cell disease patients infected with COVID-19 mostly discuss the pattern of clinical presentations and laboratory changes in patients with SCD infected with COVID-19. This review of literature assesses the prognostic indicators in sickle cell disease patients infected with COVID 19 in three major case series. Some presenting symptoms and signs, presence of comorbidities and certain laboratory parameters were compared with poor outcome of patients. Poor clinical outcomes of patients in this review included: 1. Duration of admission of ≥10 days, 2. A week or more of intensive care unit admission, 3. Death of patient despite intervention while on admission, and 4. Deterioration in the presenting comorbid clinical condition. The presenting symptoms and signs, presence of comorbidities and certain laboratory parameters associated with these poor clinical outcomes were considered as poor prognostic factors. The presence of comorbidities, markedly elevated pro-inflammatory markers such as leukocytosis, IL-6, C-reactive proteins, marked elevated D-Dimer and high serum creatinine are poor prognostic factors in sickle cell disease patients with COVID-19 infection.

show abstract

COVID‐19 infection in patients with sickle cell disease

Cited by 95 publications

References 4 publications

Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations

Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations

Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity

Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 – Review of Literatures

Contact Info

Product

Resources

About